A Phase 1, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study to Assess the Safety and Immunogenicity of an Investigational Non-Replicating Rotavirus Vaccine (MT-5625) in Healthy Adults, Toddlers and Infants
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs MT-5625 (Primary) ; RIX 4414
- Indications Rotavirus infections
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 04 Aug 2019 Status changed from active, no longer recruiting to completed.
- 17 May 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2018 Status changed from not yet recruiting to recruiting.